Nootropic and Adaptogenic Effect of Combined Use of Cortexin with Polyunsaturated Fatty Acids Concentrate under Experimental Dislipidemia

Background. We studied the effect of combined application of omega-3 polyunsaturated fatty acid concentrate, based on seals fat, with parenteral administration of brain cortex polypeptide preparation on cognitive-research reactions and adaptation of rats under experimental hyperlipidemia. The composition of the myelin sheaths of neurons is represented by a protein-lipid complex, which is a part of the cell membrane, the imbalance of which leads to a number of neurological diseases.

The aim of the study was to confirm experimentally that the combined use of drugs, based on essential polyunsaturated fatty acids and polypeptides, would influence more effectively on neurometabolic processes in neurons, compared to their application separately.

Materials and methods. Wistar rats were used. They were on a special atherogenic diet to build the model of hypercholesterolemia. The pharmacological effects of drugs were evaluated in the Open Field and Morris Water Maze tests.

Results. The study found that in rats, who received a combination of polyunsaturated fatty acids concentrate with Cortexin injections, and undergoing atherogenic diet, the overall motor activity increased significantly in the Open field test, at the same time the number of acts of defecation and grooming decreased. The Morris Water Maze test results indicated an increase in the level of spatial memory and orientation, which shows a high level of adaptability and adaptation to new conditions, a decrease in the level of anxiety.

Conclusions. The results demonstrated a more pronounced and prolonged nootropic and adaptogenic action of the complex use in comparison with the use of the studied agents as monotherapy.

1. Vereshchagin NV, Varakin YuYa. Stroke epidemiology in Russia. In: Vereshchagin NV, Piradov MA, Evzelman MA. (eds.). Neotlozhnye sostoyaniya v nevrologii: Trudy Vserossiyskogo rabochego soveshchaniya nevrologov Rossii. M.: Favor, 2002: 16-21. (In Russ.)

2. Skvortsova VI, Stakhovskaya LV, Ayrinyan NYu. Stroke epidemiology in the Russian Federation. Sistemnye gipertenzii. 2005; (1): 10-12. (In Russ.)

3. Suslina ZA. Vascular diseases of brain. In: Piradova MA, Fonyakina AV. (eds.). Trudy I Natsional’nogo kongressa «Kardionevrologiya». M.: OOO «Dialog». М.: ООО «Диалог»; 2008: 7-10. (In Russ.)

4. Petersen RS, Smith GE, Waring SC. Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archive Neurology. 1999; 56(3): 303-308. doi: 10.1001/ archneur.56.3.303

5. Gusev EI, Skvortsova VI. Cerebral ischemia. M.: Meditsina; 2001. (In Russ.) 6. Montgomery P, Burton JR, Sewell RP, Spreckelsen TF, Richardson AJ. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. PLoS One. 2013; 8(6): e66697. doi: 10.1371/journal.pone.0066697

6. Yakhno NN. Cognitive disorders in neurological clinic. Nevrologicheskiy zhurnal. 2006; (11): 4-12. (In Russ.)

7. Odinak MM, Voznyuk IA. Cerebral circulation disorders: medically induced correction of injured bloodflow. SPb.: Voennomeditsinskaya akademiya; 2006. (In Russ.)

8. Gladyshev MI. Essential polyunsaturated fatty acids and their и food sources for people. ZHurnal Sibirskogo federal’nogo universiteta. Biologiya. 2012; 5(4): 352-386. (In Russ.)

9. Dyakonov MM, Shabanov PD. Long-term experience of low-dose peptide neuroprotection in medicine. Nevrologiya i neyrokhirurgiya. Vostochnaya Evropa. 2015; 2(26): 147-153. (In Russ.)

10. Yaremenko KV. Adaptogens in phytotheraopy. I Rossiyskiy fitoterapevticheskiy sjezd: sbornik nauchnykh trudov (Moskva, 14–16 marta 2008 goda). M.: Izd-vo Federal’nogo nauchnogo klinikoeksperimental’nogo tsentra traditsionnykh metodov diagnostiki i lecheniya; 2008: 363-364. (In Russ.)

11. Alifirova VM, Dadasheva MN, Doronin BM, Kovalenko AV, Lokshtanova TM, Martynov MYu, et al. Clinical effectiveness and pharmacoeconomic characteristics of neuroprotection using low doses of Cortexin in the treatment of acute ischemic stroke. ZHurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014; (4): 41-46. (In Russ.)

12. Gerasimova MM. Effect of Cortexin on the treatment of acute period of ischemic stroke. In: Skoromets AA, Dyakonov MM. (eds.). Korteksin. 5-letniy opyt otechestvennoy nevrologii. M.: Nauka; 2006: 82-89. (In Russ.)

13. Lehninger AL, Nelson DL, Cox MM. Principles of biochemistry. N.Y.: Worth Publishers; 1993.

14. Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids. 2009; 81(2-3): 205-211. doi: 10.1016/j. plefa.2009.05.024

15. Dyall SC, Michael-Titus A. Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 2008; 10(4): 219-235. doi: 10.1007/s12017-008-8036-z

16. McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm. 2007; 64(6): 595-605. doi: 10.2146/ajhp060164

17. Radnaeva LD, Pestereva OV, Chirkina TF, Averina ES, Bodoev NV. Studying the chemical composition of Baikal seal fat. Khimiya v interesakh ustoychivogo razvitiya. 1999; (7): 713-717. (In Russ.)

18. Zhamsaranova SD, Lamazhapova GP, Syngeeva EV. Development of a method to produce a concentrate of polyunsaturated fatty acids. Biosci Biotech Res Asia. 2014; 11(2): 59-64. doi: 10.13005/ bbra/1440

19. Mironov AN. (ed.). Guidelines on preclinical researches of medicinal products. Part 1. M.: Grif i K; 2012. (In Russ.)